← Back to Clinical Trials
Recruiting NCT07183683

NCT07183683 Stimulation of Acupuncture Points in Female Patients With Multiple Sclerosis and Neurogenic Bladder Dysfunction

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT07183683
Status Recruiting
Phase
Sponsor Charite University, Berlin, Germany
Condition Neurogenic Bladder Dysfunction
Study Type INTERVENTIONAL
Enrollment 150 participants
Start Date 2025-09
Primary Completion 2026-12-30

Trial Parameters

Condition Neurogenic Bladder Dysfunction
Sponsor Charite University, Berlin, Germany
Study Type INTERVENTIONAL
Phase N/A
Enrollment 150
Sex FEMALE
Min Age 18 Years
Max Age 60 Years
Start Date 2025-09
Completion 2026-12-30
Interventions
group 1: electrical stimulation of acupuncture points plus routine caregroup 2: acupressure plus routine care

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

Brief Summary

Electrical vs. manual stimulation: The study compares two types of acupuncture - one using mild electrical currents and one using just manual no-needle techniques in the treatment of urinary bladder disfunction. The study focuses on women diagnosed with multiple sclerosis (MS) who also have neurogenic bladder dysfunction - a condition where the bladder doesn't work properly due to nerve damage.

Eligibility Criteria

Inclusion Criteria: * Female patients, aged 18-60 years, with relapsing-remitting multiple sclerosis (RRMS) and an Expanded Disability Status Scale (EDSS) score ≤ 6 * Stable immunomodulatory MS therapy for at least 3 months prior to enrollment * Presence of at least 3 out of the following 6 criteria indicative of overactive bladder dysfunction: urgency, daytime urinary frequency \>10 times, nocturia \>1 time per night, post-void dribbling, incontinence, or delayed initiation of micturition * Participants must be willing and cognitively and linguistically capable of adhering to the study protocol, performing the study interventions, and completing the required study documentation * Capacity to provide informed consent, and provision of written consent for both written and electronic data collection and participation in the study Exclusion Criteria: * Acute MS relapse within the last 3 months prior to individual study entry * Planned change in immunomodulatory therapy during the study pe

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology